Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study

Ji Hoon Kim
,
Hee-Chul Nam
ORCID logo ,
Chang Wook Kim
ORCID logo ,
Hee Sun Cho
,
Jae-Sung Yoo
,
Ji Won Han
ORCID logo ,
Jeong Won Jang
ORCID logo ,
Jong Young Choi
,
Seung Kew Yoon
ORCID logo ,
Hyun Yang
ORCID logo ,
Si Hyun Bae
ORCID logo ,
Suho Kim
ORCID logo ,
Jung-Suk Oh
,
Ho Jong Chun
ORCID logo ,
Chang Ho Chun
ORCID logo ,
Jaegyoon Ahn
ORCID logo ,
Pil Soo Sung
* ORCID logo
Version 1 : Received: 20 July 2023 / Approved: 20 July 2023 / Online: 21 July 2023 (14:00:43 CEST)

A peer-reviewed article of this Preprint also exists.

Kim, J.H.; Nam, H.-C.; Kim, C.-W.; Cho, H.S.; Yoo, J.-S.; Han, J.W.; Jang, J.W.; Choi, J.Y.; Yoon, S.K.; Yang, H.; Bae, S.H.; Kim, S.; Oh, J.S.; Chun, H.J.; Jeon, C.H.; Ahn, J.; Sung, P.S. Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study. Cancers 2023, 15, 4233. Kim, J.H.; Nam, H.-C.; Kim, C.-W.; Cho, H.S.; Yoo, J.-S.; Han, J.W.; Jang, J.W.; Choi, J.Y.; Yoon, S.K.; Yang, H.; Bae, S.H.; Kim, S.; Oh, J.S.; Chun, H.J.; Jeon, C.H.; Ahn, J.; Sung, P.S. Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study. Cancers 2023, 15, 4233.

Abstract

This study aimed to compare the prognosis and characteristics of patients with advanced hepatocellular carcinoma treated with first-line atezolizumab plus bevacizumab (AB) combination therapy and hepatic artery infusion chemotherapy (HAIC). We retrospectively assessed 179 and 72 patients treated with HAIC and AB combination therapy, respectively, between January 2018 and January 2023. The progression-free survival of patients treated with HAIC was significantly superior than that of patients treated with AB (P<0.05), but there was no significant difference in overall survival and objective response rate (ORR) between the two groups (P=0.1056 and P=0.137, respectively). After propensity score matching (PSM), our data revealed that there was no significant difference in PFS between patients who received AB combination therapy and HAIC therapy (P=0.8888). However, patients who received AB combination therapy had significantly better overall survival than those who received HAIC therapy (P=0.0133). In addition, after PSM, significant differences in ORR and disease control rate were not observed. In conclusion, our propensity score study reveals that patients treated with AB therapy have a significantly longer OS than those treated with HAIC.

Keywords

Hepatocellular carcinoma; Atezolizumab–bevacizumab; Hepatic artery infusion chemotherapy; Overall survival; Progression-free survival

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.